Ultra rapid lispro (URLi) shows faster insulin absorption vs lispro during insulin pump (CSII) use in patients with type 1 diabetes

被引：0
|
作者：
Kazda, C. [1 ]
Leohr, J. [2 ]
Liu, R. [2 ]
Hardy, T. A. [2 ]
Reddy, S. [2 ]
Chua, S. P. C. [3 ]
Guo, X. [2 ]
Hovelmann, U. [4 ]
Kapitza, C. [4 ]
机构：
[1] Lilly France, Neuilly Sur Seine, France
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Lilly NUS Ctr Clin Pharmacol Pte Ltd, Singapore, Singapore
[4] Profil Inst Stoffwechselforsch GmbH, Nuess, Germany
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
817
引用
下载
收藏
页码：S401 / S401
页数：1
相关论文
共 50 条
  • [31] The Ultra-rapid Insulin (URI) BioChaperone Lispro (BCLIS) Shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs. Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)
    Bode, Bruce W.
    Klein, Oliver
    Seroussi, Cyril
    Ranson, Aymeric
    Arrubla, Jorge
    Correia, Jose
    Gaudier, Martin
    Soula, Olivier
    Soula, Remi
    Alluis, Bertrand
    Meiffren, Gregory
    Glezer, Stanislav
    Heise, Tim
    DIABETES, 2018, 67
  • [32] Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS)
    Andersen, G.
    Alluis, B.
    Meiffren, G.
    Ranson, A.
    Seroussi, C.
    Gaudier, M.
    Soula, O.
    Fischer, A.
    Nosek, L.
    Heise, T.
    DIABETOLOGIA, 2015, 58 : S449 - S449
  • [33] Ultra rapid lispro (URLi) improves postprandial glucose (PPG) control vs lispro in type 1 diabetes: PRONTO-T1D study
    Dahl, D.
    Cao, D.
    Dellva, M.
    Tobian, J. A.
    Miura, J.
    Klaff, L.
    Bue-Vallesky, J. M.
    DIABETOLOGIA, 2019, 62 : S93 - S93
  • [34] Greater reduction in postprandial glucose excursions with Ultra Rapid Lispro (URLi) vs lispro in patients with type 2 diabetes at different meal-to-dose timings
    Plum-Moerschel, L.
    Linnebjerg, H.
    LaBell, E. Smith
    Reddy, S.
    Dellva, M.
    Hettiarachchi, H.
    Coutant, D. E.
    Hardy, T. A.
    Herbrand, T.
    Anastassiadis, E.
    Hoevelmann, U.
    Leohr, J. K.
    DIABETOLOGIA, 2019, 62 : S382 - S382
  • [35] The ultra-rapid insulin BioChaperone Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps
    Meiffren, G.
    Klein, O.
    Seroussi, C.
    Ranson, A.
    Arrubla, J.
    Correia, J.
    Gaudier, M.
    Soula, O.
    Soula, R.
    Alluis, B.
    Glezer, S.
    Heise, T.
    Bode, B.
    DIABETOLOGIA, 2018, 61 : S30 - S31
  • [36] Treatment of type 1 diabetes with insulin lispro during Ramadan
    Al-Nakhi, A
    Kadiri, A
    El-Ghazali, S
    Jabbar, A
    AL Arouj, M
    Akram, J
    Wyatt, J
    Assem, A
    Ristic, S
    DIABETES, 2000, 49 : A352 - A353
  • [37] Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2
    Warren, Mark
    Bode, Bruce
    Cho, Jang I.
    Liu, Rong
    Tobian, Janet
    Hardy, Thomas
    Chigutsa, Farai
    Phillip, Moshe
    Horowitz, Barry
    Ignaut, Debra
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1552 - 1561
  • [38] Ultra rapid lispro (URLi) improves postprandial glucose (PPG) control vs lispro in patients with type 2 diabetes: PRONTO-T2D study
    Frias, J. P.
    Zhang, Q.
    Blevins, T.
    Jinnouchi, H.
    Chang, A. M.
    DIABETOLOGIA, 2019, 62 : S384 - S384
  • [39] Ultra-rapid lispro (URLi) improves postprandial glucose control vs Humalog® (Lispro) in type 1 diabetes: PRONTO-T1D Study
    Klaff, Leslie
    Cao, Dachuang
    Dellva, Mary Anne
    Tobian, Janet
    Miura, Junnosuke
    Dahl, Dominik
    Bue-Valleskey, Juliana
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [40] Technosphere® Insulin vs Insulin Lispro in Patients with Type 1 Diabetes Using Multiple Daily Injections
    Garg, Satish K.
    McGill, Janet B.
    Rosenstock, Julio
    Hirsch, Irl B.
    Petrucci, Richard E.
    Chang, Ping-Chung
    Boss, Anders H.
    Richardson, Peter C.
    Skyler, Jay S.
    DIABETES, 2011, 60 : A250 - A250
12345